Precision Medicine

Breaking

RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup Heart Failure 2026: Vutrisiran Data & European Pharma News Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling

NewsMay 4, 2026

FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer

Guardant Health receives FDA approval for Guardant360 CDx liquid biopsy test as companion diagnostic for VEPPANU (vepdegestrant) in advanced breast cancer patients.

Michael Rivera

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer